tiprankstipranks
Trending News
More News >
Psychedelic: Exclusive talk with biotech company Clearmind Medicine
PremiumThe FlyPsychedelic: Exclusive talk with biotech company Clearmind Medicine
1M ago
Psychedelic: atai Life Sciences, NRx report quarterly results
Premium
The Fly
Psychedelic: atai Life Sciences, NRx report quarterly results
1M ago
Compass Pathways announces published study on psilocybin in depression
Premium
The Fly
Compass Pathways announces published study on psilocybin in depression
1M ago
Buy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position
PremiumRatingsBuy Rating for COMPASS Pathways: Promising Phase 3 Trial Progress and Strong Financial Position
2M ago
Compass Pathways price target lowered to $15 from $23 at Canaccord
Premium
The Fly
Compass Pathways price target lowered to $15 from $23 at Canaccord
2M ago
Compass Pathways Reports 2024 Financial Results and Progress
Premium
Company Announcements
Compass Pathways Reports 2024 Financial Results and Progress
2M ago
Positive Outlook for COMPASS Pathways Amid Psychedelic Acceptance and Strategic Investment Opportunity
PremiumRatingsPositive Outlook for COMPASS Pathways Amid Psychedelic Acceptance and Strategic Investment Opportunity
2M ago
Compass Pathways initiated with a Buy at Stifel
Premium
The Fly
Compass Pathways initiated with a Buy at Stifel
2M ago
Psychedelic: Exclusive talk with biotech company Enveric Biosciences
Premium
The Fly
Psychedelic: Exclusive talk with biotech company Enveric Biosciences
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100